Skip to main content

Research Repository

Advanced Search

Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS)

Roosenhoff, Rueshandra; Reed, Vaughan; Kenwright, Andy; Schutten, Martin; Boucher, Charles A; Monto, Arnold; Clinch, Barry; Kumar, Deepali; Whitley, Richard; Nguyen-Van-Tam, Jonathan S; Osterhaus, Albert D M E; Fouchier, Ron A M; Fraaij, Pieter L A

Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS) Thumbnail


Authors

Rueshandra Roosenhoff

Vaughan Reed

Andy Kenwright

Martin Schutten

Charles A Boucher

Arnold Monto

Barry Clinch

Deepali Kumar

Richard Whitley

Albert D M E Osterhaus

Ron A M Fouchier

Pieter L A Fraaij



Abstract

Background

We studied the effect of age, baseline viral load, vaccination status, antiviral therapy, and emergence of drug resistance on viral shedding in children infected with influenza A or B virus.

Methods

Samples from children (aged ≤13 years) enrolled during the 7 years of the prospective Influenza Resistance Information Study were analyzed using polymerase chain reaction to determine the influenza virus (sub-)type, viral load, and resistance mutations. Disease severity was assessed; clinical symptoms were recorded. The association of age with viral load and viral clearance was examined by determining the area under the curve for viral RNA shedding using logistic regression and Kaplan-Meier analyses.

Results

A total of 2131 children infected with influenza (683, A/H1N1pdm09; 825, A/H3N2; 623, influenza B) were investigated. Age did not affect the mean baseline viral load. Children aged 1−5 years had prolonged viral RNA shedding (±1–2 days) compared with older children and up to 1.2-fold higher total viral burden. Besides, in older age (odds ratio [OR], 1.08; confidence interval [CI], 1.05–1.12), prior vaccination status (OR, 1.72; CI, 1.22–2.43) and antiviral treatment (OR, 1.74; CI, 1.43–2.12) increased the rate of viral clearance. Resistance mutations were detected in 49 children infected with influenza A virus (34, A/H1N1pdm09; 15, A/H3N2) treated with oseltamivir, most of whom were aged [under]5 years (n = 39).

Conclusions

Children aged 1−5 years had a higher total viral burden with prolonged virus shedding and had an increased risk of acquiring resistance mutations following antiviral treatment.

Clinical Trials Registration

NCT00884117.

Citation

Roosenhoff, R., Reed, V., Kenwright, A., Schutten, M., Boucher, C. A., Monto, A., …Fraaij, P. L. A. (2020). Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS). Clinical Infectious Diseases, 71(5), 1186–1194. https://doi.org/10.1093/cid/ciz939

Journal Article Type Article
Acceptance Date Sep 17, 2019
Online Publication Date Sep 27, 2019
Publication Date Sep 1, 2020
Deposit Date Sep 30, 2019
Publicly Available Date Sep 28, 2020
Journal Clinical Infectious Diseases
Print ISSN 1058-4838
Electronic ISSN 1537-6591
Publisher Oxford University Press (OUP)
Peer Reviewed Peer Reviewed
Volume 71
Issue 5
Pages 1186–1194
DOI https://doi.org/10.1093/cid/ciz939
Keywords Microbiology (medical); Infectious Diseases
Public URL https://nottingham-repository.worktribe.com/output/2723258
Publisher URL https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciz939/5574924

Files




You might also like



Downloadable Citations